drugset / Trial / NCT02791191
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
RandomizedParallel-groupTriple-blindTreatment
Summary
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
Timeline
- Start
- 2016-06-16
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3202626 | Unknown | 3 mg | Oral |
| Subject | LY3202626 | Unknown | 12 mg | Oral |